Short-term changes in myocardial perfusion of the predominant donor vessel after percutaneous coronary intervention for chronic total occlusion

慢性完全闭塞经皮冠状动脉介入治疗后主要供血血管心肌灌注的短期变化

阅读:1

Abstract

BACKGROUND: It remains unclear how rapidly the collateral circulation regresses after percutaneous coronary intervention (PCI) of chronic total occlusion (CTO). This study aimed to investigate the short-term changes of myocardial perfusion in the predominant donor vessel after successful CTO PCI. METHODS: A total of 68 patients who underwent single-photon emission computerized tomography (SPECT) assessment before and within 24-72 hours after successful CTO PCI were retrospectively included into this study. The coronary flow reserve (CFR) in the CTO territory and the predominant donor vessel territory were analyzed. RESULTS: The average age of the included patients was 57.1±12.5 years old, and 88.2% were male. In the CTO territory, the CFR increased from 1.80±0.99 at baseline to 2.13±1.02 after PCI (P=0.018). In the predominant donor territory, the CFR at baseline did not significantly differ from that of after PCI (baseline: 2.12±1.09; after-PCI: 2.27±0.78; P=0.214). However, the change in CFR (ΔCFR) of the predominant donor territory was correlated with that in the CTO territory (P<0.001). The target vessel of CTO [left anterior descending artery (LAD) vs. left circumflex artery (LCX); P=0.022] and diabetes mellitus (P=0.011) were other independent factors associated with ΔCFR in the predominant donor territory. In the those treated with CTO of the LAD, CFR in the predominant donor territory increased from 1.65±0.61 at baseline to 2.30±0.75 after PCI (P=0.003). In contrast, no significant ΔCFR was not observed in those treated with CTO of the LCX or right coronary artery (RCA). CONCLUSIONS: The myocardial perfusion in the predominant donor territory was positively associated with that in the CTO territory. The myocardial perfusion in the predominant donor territory increased within a short-term period after CTO PCI, specifically in those patients with CTO of the LAD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。